Published 1 day ago • loading... • Updated 16 hours ago

Data-Driven Modeling of Amyloid-beta Targeted Antibodies for Alzheimer’s Disease

Summary by researchsquare.com

Alzheimer’s disease (AD) is caused by the build-up of amyloid beta (A$\beta$) proteins in the brain, leading to memory loss and cognitive decline. Despite the approval of monoclonal antibodies targeting A$\beta$, optimizing treatment strategies while minimizing side effects remains a challenge. T...

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All

Left

Center

Right

Clinical Trials Arena

AD/PD 2025: Roche's Brainshuttle technology promises next generation of amyloid beta mAbs

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/OD), during the 'Abeta Targeting Therapies in AD' symposium on 3 April, Roche presented interim trial data for its novel anti-amyloid monoclonal antibody (mAb), trontinemab, to clinically validate its proprietary Brainshuttle technology for the treatment of prodromal or mild to moderate AD.The post AD/PD 2025: Roche’s Brainshuttle technology promises next gene…

16 hours ago

Read Full Article

neurologylive.com

Cognito’s Gamma Sensory Stimulation Leads to Preserved Corpus Callosum Structure in Alzheimer Disease

The Spectris device demonstrated preserved corpus callosum structure and correlated sensory-evoked gamma oscillations in patients with Alzheimer disease, highlighting its potential neuroprotective effects.

1 day ago

Read Full Article